Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia
Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia
复制标题
DOI：
10.1016/j.hoc.2015.01.002
复制
发表时间：
2015-06-01
影响因子：
2.4
通讯作者：
Tjonnfjord, Geir E.
中科院分区：
文献类型：
--
作者：
Berentsen, Sigbjorn;Randen, Ulla;Tjonnfjord, Geir E.
冷抗体类型占自身免疫性溶血性贫血的约25%。原发性慢性冷凝集素病（CAD）是一种克隆性淋巴组织增生性疾病。继发性冷凝集素综合征（CAS）使特定感染和恶性肿瘤复杂化。CAD和CAS中的溶血是由经典补体途径介导的，并且主要是血管外的。并非所有患者都需要治疗。成功的CAD治疗靶向致病性B细胞克隆。在CAD和CAS中，补体调节似乎是有希望的。在临床使用之前，需要进一步开发和记录。我们审查可能的补体导向治疗的选择。
Cold antibody types account for about 25% of autoimmune hemolytic anemias. Primary chronic cold agglutinin disease (CAD) is characterized by a clonal lymphoproliferative disorder. Secondary cold agglutinin syndrome (CAS) complicates specific infections and malignancies. Hemolysis in CAD and CAS is mediated by the classical complement pathway and is predominantly extravascular. Not all patients require treatment. Successful CAD therapy targets the pathogenic B-cell clone. Complement modulation seems promising in both CAD and CAS. Further development and documentation are necessary before clinical use. We review options for possible complement-directed therapy.